News | April 25, 2024
Zydus Lifesciences gets 10 observations from USFDA for Jarod injectable facility
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
The drug will target specific genetic mutations prevalent in certain types of cancers
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Subscribe To Our Newsletter & Stay Updated
